BTIG Research Raises LifeMD (NASDAQ:LFMD) Price Target to $14.00

LifeMD (NASDAQ:LFMD) had its price objective raised by BTIG Research from $13.00 to $14.00 in a research note published on Tuesday, Benzinga reports. BTIG Research currently has a buy rating on the stock.

Separately, HC Wainwright raised their price target on shares of LifeMD from $10.00 to $12.00 and gave the stock a buy rating in a report on Thursday, January 11th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of Buy and an average price target of $10.40.

LifeMD Trading Down 3.0 %

Shares of NASDAQ LFMD opened at $10.82 on Tuesday. The company has a 50 day simple moving average of $9.32 and a 200 day simple moving average of $7.72. LifeMD has a 1 year low of $1.40 and a 1 year high of $12.01. The company has a current ratio of 1.22, a quick ratio of 1.15 and a debt-to-equity ratio of 3.22.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings results on Monday, March 11th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.02. The firm had revenue of $44.86 million for the quarter, compared to the consensus estimate of $40.65 million. Equities research analysts anticipate that LifeMD will post -0.14 EPS for the current fiscal year.

Institutional Trading of LifeMD

Several large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC grew its position in shares of LifeMD by 266.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock worth $38,000 after buying an additional 3,348 shares during the period. Cambridge Investment Research Advisors Inc. grew its position in shares of LifeMD by 24.8% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 25,200 shares of the company’s stock worth $158,000 after buying an additional 5,000 shares during the period. Dorsey Wright & Associates acquired a new stake in shares of LifeMD during the 3rd quarter worth approximately $37,000. HighMark Wealth Management LLC acquired a new stake in shares of LifeMD during the 3rd quarter worth approximately $38,000. Finally, Worth Venture Partners LLC acquired a new stake in shares of LifeMD during the 3rd quarter worth approximately $64,000. Institutional investors and hedge funds own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.